Phil,
It is interesting that the funding went to Novavax for the development of the COVID vaccine. This probably has to do with capability and record. Some of the other smaller research labs are a little farther in their clinical trials but might not have the best study design, producibility, or MOA that would fit the new data.
Do you know what the phases are?